Liminatus Pharma Receives Nasdaq Delisting Notice, Appeals Decision to Stay Suspension
LIMN sits 44% above its 52-week low of $0.132.
Summary
Liminatus Pharma received a formal delisting notice from Nasdaq for failing to meet market value requirements, but has appealed the decision, temporarily staying the delisting process.
Key Events · Corporate Governance and Compliance · LIMN
-
Nasdaq Delisting Notice Received
On May 20, 2026, Liminatus Pharma received a notice from Nasdaq stating it had not regained compliance with the $50 million market value of listed securities (MVLS) and $15 million market value of publicly held shares (MVPHS) requirements.
-
Trading Suspension Imminent
Trading of the company's common stock and warrants was scheduled for suspension at the opening of business on May 29, 2026, unless an appeal was filed.
-
Company Files Appeal
On May 26, 2026, the company requested an appeal before the Nasdaq Hearings Panel, which will result in a stay of any suspension or delisting action pending the hearing.
Analysis · LIMN · Life Sciences
Liminatus Pharma failed to regain compliance with Nasdaq's minimum market value requirements, leading to a formal delisting notice. While the company has appealed this decision, temporarily staying the delisting, the underlying issue of non-compliance and the threat of losing its Nasdaq listing remain critical. This event significantly impacts investor confidence and the company's ability to raise capital, especially given its previously disclosed 'going concern' doubts and low market capitalization. The outcome of the appeal will be a major determinant of the company's immediate future.
At the time of this filing, LIMN was trading at $0.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.1M. The 52-week trading range was $0.13 to $33.66. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.